Biotechnology industry

Q1FY271 earlier

6 companies · ₹56,120 cr · 2 with AI deep dives · Q1FY27 report

Exhibit 3Structure

₹56,120 cr

Anthem Biosciences Ltd is 93.7% of this industry by market cap. The top 5 are 100% and the top 10 are 100%.

large 1small 1micro 42 above ₹500 cr

Exhibit 5Coverage (6 of 6)

Every company here with a deep dive, topped up by market cap. The rest of the industry is in the appendix.

Mcap
₹52,845 cr
P/E
91.5x
EV/EBITDA
54.8x
ROCE
25.4%
Margin
42.3%
Rev YoY
-22.6%
Mcap
₹3,293 cr
P/E
19.8x
EV/EBITDA
12.0x
ROCE
13.6%
Margin
34.7%
Rev YoY
+2.1%
Mcap
₹136 cr
P/E
-
EV/EBITDA
-
ROCE
-2.1%
Margin
-23.6%
Rev YoY
-
Mcap
₹44 cr
P/E
-
EV/EBITDA
5.3x
ROCE
6.2%
Margin
39.6%
Rev YoY
+14.1%
Mcap
₹20 cr
P/E
-
EV/EBITDA
-
ROCE
-0.6%
Margin
8.0%
Rev YoY
+3.6%
Mcap
₹10 cr
P/E
-
EV/EBITDA
-
ROCE
1.0%
Margin
15.6%
Rev YoY
-55.6%

Exhibit 6What managements said

from Pharmaceuticals & Biotechnology earnings calls · as of 2026-06-30
tailwindIndia branded formulations delivering broad-based IPM outperformance10 managements

Every covered India-branded company reported revenue growth exceeding IPM in Q1 FY27. Sun (+16%, volume 5.4% vs IPM 2%), Torrent (+19% base vs IPM 12%), Zydus (+20%), Cipla…

  • TORNTPHARM (Q1FY27): “Torrent's India base business revenues for Q1 were INR2,157 crores, registering a growth…
7 more themes from this quarter's earnings calls are locked. A free account opens 3 full reports a quarter: every theme with verbatim management quotes, the demand picture, companies running against the tide, and the regulatory & disruption watch. Sign up free →

Exhibit 7Outlook

The outlook and what resolves next quarter

Where these managements said things are heading, and the dated, checkable events that would change it. Free with an account - 3 full reports a quarter.

Create a free account

AppendixThe other 0 companies

1-0
sort: mcap · composite · name